StreetInsider.com News Articles

Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026

Thu, 01 Oct 2026 08:00:00 -0400

MUC16 Expression Remained High and Stable Following Standard-of-Care Therapies, Supporting Its Potential Utility in Both Combination Approaches and Relapsed Settings

High MUC16 Expression Was Associated with Poor Real-World Overall Survival in High-Grade Serous Ovarian Carcinoma, the Most Common Subtype of Ovarian Cancer

Findings Reinforce the Scientific Rationale for HWK-016, Whitehawk's

Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026

Thu, 01 Oct 2026 08:00:00 -0400

MUC16 Expression Remained High and Stable Following Standard-of-Care Therapies, Supporting Its Potential Utility in Both Combination Approaches and Relapsed Settings

High MUC16 Expression Was Associated with Poor Real-World Overall Survival in High-Grade Serous Ovarian Carcinoma, the Most Common Subtype of Ovarian Cancer

Findings Reinforce the Scientific Rationale for HWK-016, Whitehawk's

Stifel Starts Whitehawk Therapeutics (WHWK) at Buy

Wed, 30 Sep 2026 16:07:23 -0400

Stifel analyst Dara Azar initiates coverage on Whitehawk Therapeutics (NASDAQ: WHWK) with a Buy rating and a price target of $9.00.
The analyst comments "We view linker-payload stability as the core differentiator of WHWK Antibody-Drug Conjugates (ADCs), compounded by target selection, biology-matched antibodies, proprietary conjugation, which we start de-risking with partner data on the same TOP1i-based linker-payload. Multiple active doses with better tolerability than a P3-ongoing ADC that built its frontline success on stability reassures us ahead of two 1H27 P1a readouts. HWK-007 applies the stability thesis to PTK7, a cancer-selective and undercrowded target for its commercial scalability, validated by an

Stifel Starts Whitehawk Therapeutics (WHWK) at Buy

Wed, 30 Sep 2026 16:07:23 -0400

Stifel analyst Dara Azar initiates coverage on Whitehawk Therapeutics (NASDAQ: WHWK) with a Buy rating and a price target of $9.00.
The analyst comments "We view linker-payload stability as the core differentiator of WHWK Antibody-Drug Conjugates (ADCs), compounded by target selection, biology-matched antibodies, proprietary conjugation, which we start de-risking with partner data on the same TOP1i-based linker-payload. Multiple active doses with better tolerability than a P3-ongoing ADC that built its frontline success on stability reassures us ahead of two 1H27 P1a readouts. HWK-007 applies the stability thesis to PTK7, a cancer-selective and undercrowded target for its commercial scalability, validated by an

Form 4/A Whitehawk Therapeutics, For: Sep 15 Filed by: Giacobello Scott M.

Fri, 18 Sep 2026 16:45:00 -0400
si-local-file:///var/storage/secattach/20260918/27081069.html

Form 4/A Whitehawk Therapeutics, For: Sep 15 Filed by: BALL BRYAN

Fri, 18 Sep 2026 16:44:00 -0400
si-local-file:///var/storage/secattach/20260918/27081064.html

Form 4/A Whitehawk Therapeutics, For: Sep 15 Filed by: Dornan David

Fri, 18 Sep 2026 16:43:00 -0400
si-local-file:///var/storage/secattach/20260918/27081060.html

Form 4/A Whitehawk Therapeutics, For: Sep 15 Filed by: Lennon David James

Fri, 18 Sep 2026 16:42:00 -0400
si-local-file:///var/storage/secattach/20260918/27081052.html

Form 4/A Whitehawk Therapeutics, For: Sep 15 Filed by: Dugan Margaret

Fri, 18 Sep 2026 16:41:00 -0400
si-local-file:///var/storage/secattach/20260918/27081039.html

Form 4 Whitehawk Therapeutics, For: Sep 15 Filed by: Lennon David James

Tue, 15 Sep 2026 19:08:00 -0400
si-local-file:///var/storage/secattach/20260915/27066131.html

Form 4 Whitehawk Therapeutics, For: Sep 15 Filed by: Dugan Margaret

Tue, 15 Sep 2026 19:07:00 -0400
si-local-file:///var/storage/secattach/20260915/27066128.html

Form 4 Whitehawk Therapeutics, For: Sep 15 Filed by: Giacobello Scott M.

Tue, 15 Sep 2026 19:07:00 -0400
si-local-file:///var/storage/secattach/20260915/27066129.html

Form 4 Whitehawk Therapeutics, For: Sep 15 Filed by: Dornan David

Tue, 15 Sep 2026 19:06:00 -0400
si-local-file:///var/storage/secattach/20260915/27066127.html

Form 4 Whitehawk Therapeutics, For: Sep 15 Filed by: BALL BRYAN

Tue, 15 Sep 2026 19:05:00 -0400
si-local-file:///var/storage/secattach/20260915/27066124.html

Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026

Sun, 13 Sep 2026 21:30:00 -0400

PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as
a Target in Second- or Later-Line EGFR NSCLC

Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed
ADC Currently in Phase 1 Development

MORRISTOWN, N.J., Sept. 13, 2026 /PRNewswire/ --

Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026

Sun, 13 Sep 2026 21:30:00 -0400

PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as
a Target in Second- or Later-Line EGFR NSCLC

Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed
ADC Currently in Phase 1 Development

MORRISTOWN, N.J., Sept. 13, 2026 /PRNewswire/ --

Form 4 Whitehawk Therapeutics, For: Sep 09 Filed by: Iyengar Vijay K

Fri, 11 Sep 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260911/27052870.html

Form 3 Whitehawk Therapeutics, For: Sep 09 Filed by: Iyengar Vijay K

Fri, 11 Sep 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260911/27052822.html

Form 8-K Whitehawk Therapeutics, For: Sep 09

Thu, 10 Sep 2026 17:02:00 -0400
si-local-file:///var/storage/secattach/20260910/27049276.html

Whitehawk Therapeutics adds former Incyte executive to its board

Thu, 10 Sep 2026 16:05:13 -0400

Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology company, has appointed Vijay Iyengar, MD, to its board of directors, effective Sept. 9, 2026.

Dr. Iyengar spent nine years in senior leadership roles at Incyte Corporation, where he was involved in the launch of five brands across eight indications and the company's expansion into more than 20 countries. During that period, Incyte's annual revenue grew from approximately $1B to more than $4B. Before Incyte, he held senior oncology roles at Novartis and was an engagement manager in the healthcare practice at McKinsey & Company.

Dr. Iyengar holds a BS in Biology from Stanford

Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors

Thu, 10 Sep 2026 16:05:00 -0400

Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs Experience
MORRISTOWN, N.J., Sept. 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody-drug conjugate (ADC) cancer treatments, today announced the appointment of Vijay Iyengar, MD, to its Board of Directors, effective September 9, 2026.
Dr. Iyengar brings more than two decades of oncology experience building and scaling global businesses, leading strategic transactions across development-stage and commercial assets and guiding product portfolios from early

Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors

Thu, 10 Sep 2026 16:05:00 -0400

Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs Experience
MORRISTOWN, N.J., Sept. 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody-drug conjugate (ADC) cancer treatments, today announced the appointment of Vijay Iyengar, MD, to its Board of Directors, effective September 9, 2026.
Dr. Iyengar brings more than two decades of oncology experience building and scaling global businesses, leading strategic transactions across development-stage and commercial assets and guiding product portfolios from early

Form SCHEDULE 13G/A Whitehawk Therapeutics, Filed by: ORBIMED ADVISORS LLC

Fri, 14 Aug 2026 17:59:00 -0400
si-local-file:///var/storage/secattach/20260814/26933076.html

Form SCHEDULE 13G/A Whitehawk Therapeutics, Filed by: ORBIMED ADVISORS LLC

Fri, 14 Aug 2026 17:59:00 -0400
si-local-file:///var/storage/secattach/20260814/26933076.html

Form SCHEDULE 13G/A Whitehawk Therapeutics, Filed by: ABG Management Ltd.

Fri, 14 Aug 2026 16:35:00 -0400
si-local-file:///var/storage/secattach/20260814/26931625.html